乳腺浸润性导管癌组织中FOXM1、PLK1、HIF-1α和EZH2的表达及其临床意义

Expression of FOXM1,PLK1,HIF-1αand EZH2 in invasive ductal carcinoma of breast and its clinical significance

目的:分析乳腺浸润性导管癌组织中FOXM1、PLK1、HIF-1α以及EZH2的表达及其临床意义。方法:通过免疫组化检测FOXM1、PLK1、HIF-1α及EZH2蛋白在290例乳腺浸润性导管癌(观察组)和290例癌旁乳腺组织(对照组)中的表达水平,对比蛋白表达水平的差异,分析其相关性。结果:FOXM1、EZH2、PLK1和HIF-1α在乳腺癌组织中的阳性表达率分别为59.31%、28.28%、44.48%和61.03%,均明显高于其在癌旁组织中的阳性表达率(分别为29.31%、0%、3.45%和19.66%),差异有统计学意义(P<0.05)。四种蛋白的阳性表达与组织学分级、淋巴结转移情况以及临床分期显著相关,与年龄、肿瘤直径以及月经状态无关;四种蛋白两两呈正相关关系。ER阴性标本中PLK1、HIF-1α和EZH2的阳性表达率明显高于ER阳性标本;HER-2阳性标本中EZH2、FOXM1的阳性表达率明显高于HER-2阴性标本(P<0.05)。结论:FOXM1、PLK1、HIF-1α和EZH2在乳腺浸润性导管癌组织中显著表达,其表达水平的升高与癌组织分级及淋巴结转移的关系密切,其表达和相关性能为乳腺癌的病理及临床评估提供更有价值的参考。

Objective:To investigate the expression of FOXM1,PLK1,HIF-1αand EZH2 in invasive ductal carcinoma of breast and its clinical significance.Methods:The FOXM1,PLK1,HIF-1αand EZH2 proteins were detected by immunohistochemistry in 290 cases of invasive ductal carcinoma of breast(observation group)and 290 cases of adjacent breast tissues(control group).Compare the expression rates of them and then analyze the correlation among the four proteins.Results:The positive expression rates of FOXM1,EZH2,PLK1 and HIF-1αin breast cancer tissues were 59.31%,28.28%,44.48%and 61.03%respectively,which were significantly higher than the adjacent tissues(29.31%,0%,3.45%and 19.66%).The positive expression of four proteins was positively correlated with the histological grading,lymph node metastasis and clinical stage,but not with age,tumor diameter or menstruation,and they were positively correlated.The expression rates of PLK1,HIF-1αand EZH2 in ER negative samples were significantly higher than the positive samples,and the expression rates of EZH2 and FOXM1 in HER-2 positive samples were significantly higher than the negative samples(P<0.05).Conclusion:FOXM1,PLK1,HIF-1αand EZH2 were significantly expressed in breast invasive ductal carcinoma.The analysis of the expression level and its correlation can provide a more valuable reference for the pathological and clinical evaluation of invasive ductal carcinoma of breast.